OBJECTIVE: To evaluate the effectiveness of a cognitive behavioral group-based intervention aimed at reducing depression and fostering quality of life and psychological well-being of multiple sclerosis patients through the promotion of identity redefinition, sense of coherence, and self-efficacy. DESIGN: A randomized controlled trial. SETTING: Non-medical setting, external to the Multiple Sclerosis Clinic Centre. SUBJECTS:Eighty-two patients: 64% women; mean age 40.5, SD = 9.4; 95% with relapsing-remitting multiple sclerosis; Expanded Disability Status Scale (EDSS) between 1 and 5.5 were included in the study. INTERVENTIONS: Patients were randomly assigned to an intervention group (five cognitive behavioral group-based sessions, n = 41) or to a control group (three informative sessions, n = 41). MAIN MEASURES: Depression (CES-D), Quality of life (MSQOL revised), Psychological well-being (PANAS), Identity Motives Scale, Sense of Coherence (SOC), and Self Efficacy in Multiple Sclerosis. RESULTS:Quality of life increased in the intervention group compared with the control at 6-months follow-up (mean change 0.72 vs. -1.76, p < 0.05). Well-being in the intervention group increased for males and slightly decreased for females at 6-months follow-up (mean change 6.58 vs. -0.82, p < 0.05). Contrasts revealed an increase in self-efficacy in the intervention group at posttreatment compared with the control (mean change 2.95 vs. -0.11, p < 0.05). Depression tended to lower, while identity and coherence increased in the intervention group compared with the control, though the differences were not significant. CONCLUSIONS: Preliminary evidence suggests that intervention promotes patients' quality of life and has an effect on psychological well-being and self-efficacy.
RCT Entities:
OBJECTIVE: To evaluate the effectiveness of a cognitive behavioral group-based intervention aimed at reducing depression and fostering quality of life and psychological well-being of multiple sclerosispatients through the promotion of identity redefinition, sense of coherence, and self-efficacy. DESIGN: A randomized controlled trial. SETTING: Non-medical setting, external to the Multiple Sclerosis Clinic Centre. SUBJECTS: Eighty-two patients: 64% women; mean age 40.5, SD = 9.4; 95% with relapsing-remitting multiple sclerosis; Expanded Disability Status Scale (EDSS) between 1 and 5.5 were included in the study. INTERVENTIONS:Patients were randomly assigned to an intervention group (five cognitive behavioral group-based sessions, n = 41) or to a control group (three informative sessions, n = 41). MAIN MEASURES: Depression (CES-D), Quality of life (MSQOL revised), Psychological well-being (PANAS), Identity Motives Scale, Sense of Coherence (SOC), and Self Efficacy in Multiple Sclerosis. RESULTS: Quality of life increased in the intervention group compared with the control at 6-months follow-up (mean change 0.72 vs. -1.76, p < 0.05). Well-being in the intervention group increased for males and slightly decreased for females at 6-months follow-up (mean change 6.58 vs. -0.82, p < 0.05). Contrasts revealed an increase in self-efficacy in the intervention group at posttreatment compared with the control (mean change 2.95 vs. -0.11, p < 0.05). Depression tended to lower, while identity and coherence increased in the intervention group compared with the control, though the differences were not significant. CONCLUSIONS: Preliminary evidence suggests that intervention promotes patients' quality of life and has an effect on psychological well-being and self-efficacy.
Entities:
Keywords:
Multiple sclerosis; cognitive behavioral therapy; depression; group therapy; identity; quality of life; self-efficacy; sense of coherence; well-being
Authors: Joep van Agteren; Matthew Iasiello; Laura Lo; Jonathan Bartholomaeus; Zoe Kopsaftis; Marissa Carey; Michael Kyrios Journal: Nat Hum Behav Date: 2021-04-19
Authors: Aaron P Turner; Kevin N Alschuler; Abbey J Hughes; Meghan Beier; Jodie K Haselkorn; Alicia P Sloan; Dawn M Ehde Journal: Curr Neurol Neurosci Rep Date: 2016-12 Impact factor: 5.081
Authors: Thiago H Freitas; Elias Andreoulakis; Gilberto S Alves; Hesley L L Miranda; Lúcia L B C Braga; Thomas Hyphantis; André F Carvalho Journal: World J Gastroenterol Date: 2015-06-07 Impact factor: 5.742
Authors: Thomas Hyphantis; Panagiota Goulia; Ioannis Zerdes; Solomis Solomou; Elias Andreoulakis; André F Carvalho; Nicholas Pavlidis Journal: Dig Dis Sci Date: 2015-08-20 Impact factor: 3.199
Authors: Panagiota Goulia; Paraskevi V Voulgari; Niki Tsifetaki; Elias Andreoulakis; Alexandros A Drosos; André F Carvalho; Thomas Hyphantis Journal: Rheumatol Int Date: 2014-09-21 Impact factor: 2.631
Authors: Jessica Podda; Andrea Tacchino; Ludovico Pedullà; Margherita Monti Bragadin; Mario Alberto Battaglia; Giampaolo Brichetto Journal: Mult Scler Date: 2020-10-13 Impact factor: 5.855